PDF(Pubmed)
Abstract：
UNASSIGNED: Versican is a chondroitin sulphate proteoglycan with raised expression at site of inflammation, and uterine fibroids are associated with local inflammation. Hence, this study aimed to estimate serum Versican levels in pre-menopausal women with uterine fibroids to evaluate its diagnostic efficiency.
UNASSIGNED: This case-control study included forty uterine fibroid cases and 40 healthy controls. Cases clinically evaluated with USG findings, that is number, location of fibroid and volume calculated by prolate ellipse formula a × b × c × 0.523 (a - height, b - width, c - depth). Biochemical investigations, that is serum Versican levels, were estimated by ELISA with total cholesterol, HDLc and LDLc. Triglycerides by fully automated chemistry analysers. Serum biochemical parameters were compared and correlated with volume of fibroid. Area under receiver operating characteristic curve was calculated along with cut-off value to determine diagnostic potential of Versican, differentiating women with fibroids.
UNASSIGNED: In the present study, patients with fibroids had decreased levels of serum Versican (79.43 ± 18.60) as compared to healthy controls (101.81 ± 28.24, P < 0.001). There was a statistically significant negative correlation (r = - 0. 307, P = 0.04) between serum Versican level and volume of fibroid. Area under ROC was 0.726 (95% CI: 0.616-0.836; P = 0.001). The best cut-off value for serum Versican level was 96.90 ng/ml with 90% sensitivity and 48% specificity.
UNASSIGNED: Serum Versican levels were found significantly lower in women with fibroid with a negative correlation with volume of fibroid uterus. Furthermore, extensive study would help in substantiating diagnostic potential of serum Versican in fibroid uterus patients.
UNASSIGNED: This case-control study included forty uterine fibroid cases and 40 healthy controls. Cases clinically evaluated with USG findings, that is number, location of fibroid and volume calculated by prolate ellipse formula a × b × c × 0.523 (a - height, b - width, c - depth). Biochemical investigations, that is serum Versican levels, were estimated by ELISA with total cholesterol, HDLc and LDLc. Triglycerides by fully automated chemistry analysers. Serum biochemical parameters were compared and correlated with volume of fibroid. Area under receiver operating characteristic curve was calculated along with cut-off value to determine diagnostic potential of Versican, differentiating women with fibroids.
UNASSIGNED: In the present study, patients with fibroids had decreased levels of serum Versican (79.43 ± 18.60) as compared to healthy controls (101.81 ± 28.24, P < 0.001). There was a statistically significant negative correlation (r = - 0. 307, P = 0.04) between serum Versican level and volume of fibroid. Area under ROC was 0.726 (95% CI: 0.616-0.836; P = 0.001). The best cut-off value for serum Versican level was 96.90 ng/ml with 90% sensitivity and 48% specificity.
UNASSIGNED: Serum Versican levels were found significantly lower in women with fibroid with a negative correlation with volume of fibroid uterus. Furthermore, extensive study would help in substantiating diagnostic potential of serum Versican in fibroid uterus patients.
摘要：
■Versican是一种硫酸软骨素蛋白聚糖，在炎症部位表达升高，子宫肌瘤与局部炎症有关。因此，本研究旨在评估绝经前子宫肌瘤患者的血清Versican水平,以评估其诊断效能.
这项病例对照研究包括40例子宫肌瘤病例和40例健康对照。根据USG结果进行临床评估的病例，那是数字,纤维瘤的位置和体积由长椭圆公式a×b×c×0.523计算(a-高度，b-宽度,c-深度)。生化调查，那就是血清Versican水平,用总胆固醇酶联免疫吸附测定，HDLc和LDLc。甘油三酯由全自动化学分析仪。比较血清生化指标，并与肌瘤体积相关。计算受试者工作特性曲线下的面积以及临界值，以确定Versican的诊断潜力，区分患有子宫肌瘤的妇女。
■在本研究中，与健康对照组(101.81±28.24,P<0.001)相比,肌瘤患者的血清Versican水平降低(79.43±18.60).存在统计学上显著的负相干(r=-0。307，P=0.04）在血清Versican水平和肌瘤体积之间。ROC下面积为0.726（95％CI：0.616-0.836；P=0.001）。血清Versican水平的最佳临界值为96.90ng/ml，敏感性为90％，特异性为48％。
■子宫肌瘤患者血清Versican水平明显降低，与子宫肌瘤体积呈负相关。此外，广泛的研究将有助于证实血清Versican在子宫肌瘤患者中的诊断潜力。
这项病例对照研究包括40例子宫肌瘤病例和40例健康对照。根据USG结果进行临床评估的病例，那是数字,纤维瘤的位置和体积由长椭圆公式a×b×c×0.523计算(a-高度，b-宽度,c-深度)。生化调查，那就是血清Versican水平,用总胆固醇酶联免疫吸附测定，HDLc和LDLc。甘油三酯由全自动化学分析仪。比较血清生化指标，并与肌瘤体积相关。计算受试者工作特性曲线下的面积以及临界值，以确定Versican的诊断潜力，区分患有子宫肌瘤的妇女。
■在本研究中，与健康对照组(101.81±28.24,P<0.001)相比,肌瘤患者的血清Versican水平降低(79.43±18.60).存在统计学上显著的负相干(r=-0。307，P=0.04）在血清Versican水平和肌瘤体积之间。ROC下面积为0.726（95％CI：0.616-0.836；P=0.001）。血清Versican水平的最佳临界值为96.90ng/ml，敏感性为90％，特异性为48％。
■子宫肌瘤患者血清Versican水平明显降低，与子宫肌瘤体积呈负相关。此外，广泛的研究将有助于证实血清Versican在子宫肌瘤患者中的诊断潜力。
